Comparative pharmacology of the optical isomers of ketamine in mice

doi:10.1016/0014-2999(78)90217-0

European Journal of Pharmacology

Volume 49, Issue 1, 1 May 1978, Pages 15-23

https://doi.org/10.1016/0014-2999(78)90217-0 Get rights and content

Abstract

Relative pharmacology potencies of the optical isomers of ketamine have been estimated in ICR mice. The (+)-isomer was 3× more potent than (−)-ketamine as an analgesic using the phenylquinone writhing test, only 1.5 × more potent in terms of hypnotic activity 1.8 more potent in causing locomotor stimulation. At equianalgesic doses (+)-ketamine caused less stimulation of locomotor activity than the (−)-isomer. These potency differences did not appear to be due to differences in biodisposition although stereoselective metabolism was demonstrated in vivo. Analgesia induced by ketamine was reversed by 10 mg.kg of naloxone.

References (22)

L.M. Gunne et al.
Stereoselective metabolism of amphetamine
Biochem. Pharmacol.
(1967)
P.S. Portoghese
Stereochemical factors and receptor interactions associated with narcotic analgesics
J. Pharm. Sci.
(1966)
B.S. Berkowitz et al.
Nitrous oxide “analgesia”: resemblence to opiate action
Science
(1979)
K. Blum et al.
Naloxone-induced inhibition of ethanol dependence in mice
Nature
(1977)
T. Chang et al.
A gas chromatographic assay for ketamine in human plasma
Anesthesiology
(1972)
T. Chang et al.
Intern. Anesth. Clin.
(1974)
M.L. Cohen et al.
Distribution in the brain and metabolism of ketamine in the rat after intravenous administration
Anesthesiology
(1973)
G. Corssen et al.
Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phenylcyclidine derivative CI-581
Anesth. Analg.
(1966)
E.F. Domino et al.
Pharmacologic effects of CI-581, a new dissociative anesthetic, in man
Clin. Pharmacol. Therap.
(1965)
L.G. Dring et al.
The metabolic fate of amphetamine in man and other species
Biochem. j.
(1970)

J.W. Dundee et al.

Intravenous Anesthesia

(1974)

Cited by (152)

Role of the mesolimbic dopamine pathway in the antidepressant effects of ketamine
2023, Neuropharmacology
Depression is a complex and highly heterogeneous disorder which diagnosis is based on an exceedingly variable set of clinical symptoms. Current treatments focus almost exclusively on the manipulation of monoamine neurotransmitter systems, but despite considerable efforts, these remain inadequate for a significant proportion of those afflicted by the disorder. The emergence of racemic (R, S)-ketamine as a fast-acting antidepressant has provided an exciting new path for the study of major depressive disorder (MDD) and the search for better therapeutics for its treatment. Previous work suggested that ketamine's mechanism of action is primarily mediated via blockaded of N-methyl-d-aspartate (NMDA) receptors, however, this is an area of active research and clinical and preclinical evidence now indicate that ketamine acts on multiple systems. The last couple of decades have cemented the mesolimbic dopamine reward pathway's involvement in the pathogenesis of MDD and related mood disorders. Exposure to negative stress dysregulates dopamine neuronal activity disrupting reward and motivational processes resulting in anhedonia (lack of pleasure), a hallmark symptom of depression. Although the mechanism(s) underlying ketamine's antidepressant activity continue to be elucidated, current evidence indicate that its therapeutic effects are mediated, at least in part, via long-lasting synaptic changes and subsequent molecular adaptations in brain regions within the mesolimbic dopamine system. Notwithstanding, ketamine is a drug of abuse, and this liability may pose limitations for long term use as an antidepressant. This review outlines the current knowledge of ketamine's actions within the mesolimbic dopamine system and its abuse potential.
This article is part of the Special Issue on ‘Ketamine and its Metabolites’.
Injectable anesthetics
2023, Anesthesia and Analgesia in Laboratory Animals
Injectable anesthetics are commonly used in laboratory animal medicine. This chapter outlines the majority of injectable anesthetics and injectable combinations used in laboratory animals today. Pharmacokinetics, preparation and route of administration, and side effects seen with these anesthetics are covered in detail. While not always as commonly used, injectable anesthetic delivery systems are also covered in this chapter.
The opioid system in depression
2022, Neuroscience and Biobehavioral Reviews
Opioid receptors are widely distributed throughout the brain and play an essential role in modulating aspects of human mood, reward, and well-being. Accumulating evidence indicates the endogenous opioid system is dysregulated in depression and that pharmacological modulators of mu, delta, and kappa opioid receptors hold potential for the treatment of depression. Here we review animal and clinical data, highlighting evidence to support: dysregulation of the opioid system in depression, evidence for opioidergic modulation of behavioural processes and brain regions associated with depression, and evidence for opioidergic modulation in antidepressant responses. We evaluate clinical trials that have examined the safety and efficacy of opioidergic agents in depression and consider how the opioid system may be involved in the effects of other treatments, including ketamine, that are currently understood to exert antidepressant effects through non-opioidergic actions. Finally, we explore key neurochemical and molecular mechanisms underlying the potential therapeutic effects of opioid system engagement, that together provides a rationale for further investigation into this relevant target in the treatment of depression.
Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence
2022, Journal of the Neurological Sciences
Ketamine is an anesthetic drug which is now used to treat chronic pain conditions and psychiatric disorders, especially depression. It is an N-methyl-D-aspartate (NMDA) receptor antagonist with additional effects on α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, opioid receptors, and monoaminergic receptors. This article focuses on ketamine’s role in treating depression and pain, two commonly comorbid challenging conditions with potentially shared neurobiologic circuitry. Many clinical trials have utilized intravenous or intranasal ketamine for treating depression and pain. Intravenous ketamine is more bioavailable than intranasal ketamine and both are effective for acute depressive episodes. Intravenous ketamine is advantageous for post-operative analgesia and is associated with a reduction in total opioid requirements. Few studies have treated chronic pain or concurrent depression and pain with ketamine. Larger, randomized control trials are needed to examine the safety and efficacy of intravenous vs. intranasal ketamine, ideal target populations, and optimal dosing to treat both depression and pain.
Arylcyclohexamines
2021, Novel Psychoactive Substances: Classification, Pharmacology and Toxicology
The arylcyclohexamines are a group of psychoactive agents broadly derived from a cyclohexamine unit with an aryl moiety. The major agents in this group include phencyclidine, ketamine and methoxetamine, which expand into analogues and derivative agents. Their common shared property involves antagonism of the NMDA glutamate receptor. The chapter reviews the effects of each of the major agents by examining the latest animal and human evidence on acute and chronic toxicity from case reports, clinical studies and reported deaths. To complete the chapter, other new arylcyclohexamine agents are identified and briefly reviewed for their clinical effect and prevalence to alert the reader to their growing influence within the novel psychoactive drug scene. These structurally and pharmacodynamically similar derivates include methoxphenidine and several methoxy- analogues of phencyclidine.
Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine
2019, Pharmacology Biochemistry and Behavior
The N-methyl-d-aspartate receptor (NMDAR) antagonist (R,S)-ketamine produces rapid and sustained antidepressant effects in treatment-resistant patients with depression although intranasal use of (R,S)-ketamine in ketamine abusers is popular. In March 5, 2019, nasal spray of (S)-ketamine for treatment-resistant depression was approved as a new antidepressant by the US Food Drug Administration. Clinical study of (R)-ketamine is underway. In a chronic social defeat stress (CSDS) model, we compared the antidepressant effects of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine after a single intranasal administration. Furthermore, we also compared the side effects (i.e., locomotion, prepulse inhibition (PPI), abuse liability) of these three compounds in mice. The order of potency of antidepressant effects after a single intranasal administration was (R)-ketamine > (R,S)-ketamine > (S)-ketamine. In contrast, the order of locomotor activity and prepulse inhibition (PPI) deficits after a single intranasal administration was (S)-ketamine > (R,S)-ketamine > (R)-ketamine. In the conditioned place preference (CPP) test, both (S)-ketamine and (R,S)-ketamine increased CPP scores in mice after repeated intranasal administration, in a dose dependent manner. In contrast, (R)-ketamine did not increase CPP scores in mice. These findings suggest that intranasal administration of (R)-ketamine would be a safer antidepressant than (R,S)-ketamine and (S)-ketamine.

View all citing articles on Scopus

^☆: This is publication No. 77-25 from the Department of Pharmacology, University of California, San Francisco.

^∗∗: This work represents partial fulfillment of the requirements for the degree of Doctor of Philosophy.

View full text

Comparative pharmacology of the optical isomers of ketamine in mice☆

Abstract

Biochem. Pharmacol.

J. Pharm. Sci.

Nitrous oxide “analgesia”: resemblence to opiate action

Science

Naloxone-induced inhibition of ethanol dependence in mice

Nature

A gas chromatographic assay for ketamine in human plasma

Anesthesiology

Intern. Anesth. Clin.

Distribution in the brain and metabolism of ketamine in the rat after intravenous administration

Anesthesiology

Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phenylcyclidine derivative CI-581

Anesth. Analg.

Pharmacologic effects of CI-581, a new dissociative anesthetic, in man

Clin. Pharmacol. Therap.

The metabolic fate of amphetamine in man and other species

Biochem. j.

Intravenous Anesthesia